South Korea-based DAAN Biotherapeutics has signed an exclusive licensing agreement with LigaChem Biosciences for a novel tumor-targeting antibody to advance the development and commercialization of Antibody-Drug Conjugates (ADC).
By leveraging DAAN Biotherapeutics’ next-generation antibody technology, built upon its exceptional target discovery and antibody development capabilities, LigaChem Biosciences is now positioned to take a significant step forward in ADC development for solid tumor patients.
DAAN Biotherapeutics has successfully established a proprietary pipeline for efficiently developing antibodies targeting over-expressed tumor targets in solid cancers through a strategic partnership with OmniAb.
“We will continue to develop state-of-the-art antibodies targeting solid tumors and collaborate with global pharmaceutical companies in the ADC field,” noted Byoung Chul Cho, MD, and Choef Executive Officer of DAAN Biotherapeutics.
“Beyond ADCs, we also aim to become a global leader in solid tumor-targeting T-cell engagers using our proprietary TACTIC (Tumor Targeting Conditionally Activated T Cell Engager) platform,” Cho concluded.
Featured image Seoul, 大韓民国; © 2020 – 2025 by Yu Kato on Unsplash License. Used with permission.
DOI
